medigraphic.com

2010, Number 2

<< Back Next >>

Rev Med MD 2010; 1.2 (2)

Multiple Sclerosis in Pediatrics

Gutiérrez-Rubio AA

Language: Spanish
References: 18
Page: 98-102
PDF size: 494.78 Kb.


ABSTRACT

Multiple Sclerosis (MS) is an inflammatory demyelinating process of the central nervous system which can have focal, motor, sensitive and cognitive manifestations. Early onset SM occurs before 16 years of age, being more frequent in men than in women. Genetic and immunologic factors are involved in triggering the disease, although no specific agent has been outlined.
Diagnostic and therapeutical approach can be difficult in pediatric patients, which is why adult diagnostic criteria has been adapted, resulting in postponed diagnosis, inadequate treatments and poor prognosis for children with this disease.


REFERENCES

  1. Lyncet–Mejorado, D., Barragán–Pérez, E. Múltiple sclerosis in children at Hospital Infantil de Mexico Federico Gomez: an 11 year experience. Bol. Med. Hosp Infant Mex 2006; 63 (1).

  2. Stüve O., Oksenberg J. Multiple Sclerosis Overview. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle.

  3. Peña J., Montiel-Nava C., Ravelo M., González S., y Mora-LaCruz E. Esclerosis Múltiple en niños: clarificando su ubicación dentro del espectro desmielinizante. Invest clín 2006; 47(4).

  4. Espinoza, E. et al. Guías de manejo de esclerosis múltiple en niños. Acta Neurol Colomb 2002;18(3).

  5. Ben-Zacharia M.L. Conocimientos básicos de genética en esclerosis múltiple. Consortium of MS Centers.

  6. Patel Y., Bhise V., Krupp L., Pediatric multiple sclerosis. Ann Indian Acad Neurol 2009 Oct–Dec; 12(4): 238–245.

  7. Rivera V., Avila M. Esclerosis múltiple en latinoamerica ¿Son los criterios de McDonald realmente aplicables? Rev Mex Neuroci 2007; 89 (1): 49-56.

  8. Ebers G. Environmental factors and multiple sclerosis. Lanc Neu 2008; 7 (I3):268-277.

  9. O'Connor KC., et al. Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. J Neuroimmunol 2010; 223(1-2):92-9.

  10. Esclerosis Múltiple: Esperanza en la Investigación. NINDS 2003, Rev. April 28, 2010

  11. Horstman L., Jy W., Ahn Y., Zivadinov R., Maghzi A., Etemadifar M., Steven A., Minagar A. Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation 2010; 7:10. 11. Gallud L., Bagan J.V., Cervelló A., Jiménez Y., Poveda R, Gavalda C. Multiple sclerosis as first manifestation in oral and facial area: Presentation of four cases. Med Oral Patol Oral Cir Bucal 2006;11:E141

  12. Etemadifar M., Nasr-Esfahani A.H., Khodabandehlou R., et al. Childhood-Onset Multiple Sclerosis: Report of 82 Patients from Isfahan, Iran. Arch Iranian Med 2007; 10(2):152–156.

  13. Ketelslegers I.A., et al. A comparison of MRI criteria for diagnosing pediatric ADEM and MS. Neurology 2010;74(18):1404-5.

  14. Podman et al. Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the “McDonald Criteria”. Ann Neurol 2005;58:840–846

  15. Lycklama G., Thompson A., Filippi M. y cols. Resonancia Magnética Nuclear de Médula en Esclerosis Múltiple. Lanc Neu 2003;2:555-562,

  16. Esclerosis Múltiple pediátrica, VII Reunión Latinoamericana en Esclerosis Múltiple en Bariloche, 26 de Mayo: Día Mundial de la Esclerosis Múltiple.

  17. Ravnborg M. et al. Methylprednisolone in combination with interferon beta- 1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lanc Neu 2010;9(I7):672-680.

  18. Manual de fisioterapia. Modulo II. Neurología, Pediatría y Fisioterapia respiratoria, Ed Mad Sevilla, España, Nov 2004.




2020     |     www.medigraphic.com